Home › Treatments › CAR-T therapy

CAR-T and cell therapy

CAR-T therapy in China: what it costs, who qualifies, and how long it takes

China has several CAR-T products licensed by its regulator, the NMPA, and an active research programme. This page sets out the facts, the timeline and the risks, without overselling it. Whether CAR-T is appropriate is a decision for your treating haematologist.

Ask how the process works See the 6–8 week process

What CAR-T actually is

Your own T-cells are collected, genetically modified in a laboratory to recognise your cancer, multiplied, and infused back into you. It is used for certain blood cancers, usually after other treatments. Response rates reported in trials vary by product and disease; your haematologist can explain what the evidence shows for your situation.

It is not a gentle treatment. It requires weeks on the ground, hospital monitoring, and a team experienced in managing its side effects. That experience is the main reason patients travel for it.

Licensed products

CAR-T products licensed in China

Product	Target	Approved indication in China
Relmacabtagene autoleucel	CD19	Relapsed / refractory large B-cell lymphoma
Axicabtagene ciloleucel	CD19	Relapsed / refractory large B-cell lymphoma
Equecabtagene autoleucel	BCMA	Relapsed / refractory multiple myeloma
Ciltacabtagene autoleucel	BCMA	Relapsed / refractory multiple myeloma
Inaticabtagene autoleucel	CD19	Relapsed / refractory B-cell ALL

Licensed by China's National Medical Products Administration (NMPA). Approvals change; current status and pricing are confirmed with the hospital in writing before you commit.

Approved is not the same as available. A product being licensed in China does not mean it is licensed where you live, and it does not mean you are eligible for it. Eligibility is decided by the treating hospital after reviewing your pathology and treatment history.

Trials

How clinical trials work for international patients

Clinical trials test investigational products, and their benefit is not established. Each study sets its own entry criteria, costs and rules on non-resident participants, and all are listed on public registries.

Screening for a trial can take longer than for licensed treatment, and entry is never certain. Discuss any trial with your own doctor before applying.

We will never promise enrolment. Trial entry is decided by the investigating team against published inclusion criteria. We can point you to the official registry entry and help with travel and logistics if you are accepted.

Eligibility

Typical criteria in product labels

Usually required

Confirmed diagnosis of a qualifying blood cancer
Relapsed or refractory disease
At least two prior lines of treatment failed
Adequate heart, liver and kidney function
Able to carry out normal daily activity (ECOG 0–1)

What we need from you

Pathology report and biopsy results
Full treatment history, line by line
Most recent imaging (CT / PET / MRI)
Current bloods and organ function tests
Any prior transplant or cell therapy records

Every product has its own criteria. Eligibility is decided only by the treating hospital.

The process

Six to eight weeks, start to finish

Evaluation · 3–5 days

Bloods, imaging, bone marrow biopsy, cardiac assessment.

Confirms eligibility

Collection · 3–4 hours

T-cells separated from your blood and sent to the manufacturing facility.

Then you wait

Manufacturing · 2–4 weeks

Cells are modified and multiplied. Many patients rest locally during this window.

No hospital stay needed

Infusion & monitoring · 2 weeks

Conditioning chemotherapy, infusion, then close monitoring for side effects.

Hospital stay required

Risks you must hear before you decide. Cytokine release syndrome (CRS) occurs in roughly 50–80% of patients and ranges from flu-like symptoms to cases needing intensive care. Neurotoxicity (ICANS) occurs in 20–40% and is usually reversible. Prolonged low blood counts can last months. These are serious risks; ask the hospital about its own experience in managing them.

What we handle

Where Moso Health fits

Before

Initial enquiry (non-clinical)
Written opinion arranged with locally licensed doctors in China
Hospital coordination

During

Visa, flights, accommodation near the hospital
Medical interpreter at every appointment
Someone physically with you for 6–8 weeks

After

English medical records and imaging reports
Monitoring schedule for your doctor at home
Itemised invoices for your insurer

Considering care in China?

Tell us briefly what you need. If China is not the right answer, we will say so first.

What happens next

We read your enquiry
We reply within 48 hours
If we can help, scope and fees in writing

Medical concierge · reply within 48 hours